Selzentry (Maraviroc, Celsentri): News & Research

Treatment Action Group Supports Maraviroc Approval (May 1, 2007)
From Treatment Action Group
FDA Panel Recommends Agency Approve Pfizer's Antiretroviral Maraviroc (April 25, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
CROI: Maraviroc Shows Potent Effect in Highly Treatment-Experienced (February 28, 2007)
From aidsmap.com
Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Maraviroc + OBT Potent in Treatment-Experienced HIV-Infected Patients: An Interview With Roy Gulick, M.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
FDA Panel to Consider Pfizer's Second-Line HIV Drug (February 9, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Next HIV Therapies (February 2007)
MK-0518, TMC125 and Maraviroc.
In HIV JournalView, from TheBodyPRO.com
United States: Pfizer to Expand Access to HIV Drug (December 5, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
HIV Antiretroviral Agents in Development: Entry Inhibitors (March 30, 2006)
From TheBody.com
Once-Daily Arm in Maraviroc Treatment-Naive Study Terminated (January 30, 2006)
From aidsmap.com
Case Study of a Patient With Serious Hepatotoxicity in Maraviroc 2b/3 Trial Reported at Targeting HIV Entry -- 1st International Workshop (December 3, 2005)
To read PDF, click here.
From Pfizer, Inc.
The CCR5 Antagonist UK-427,857 (Maraviroc) Shows Strong Activity in Phase 1/2a Monotherapy Studies (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Entry Inhibitors in Development (July 2004)
Brief updates on PRO 542, SCH-D, UK-427,857 and GW-873140.
To read PDF, click here.
In Project Inform Perspective, from Project Inform

< Previous | 1 | 2 | 3

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's New! TheBody.com App
TheBody.com's Medication and Health Reminders
TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. ASO Finder U.S. ASO Listings
International ASOs

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.